We studied insulin degradation in human cultured lymphocytes (RPMI-1788 line)
After initial receptor binding on the cell surface, the cell-associated insulin molecules are internalized and degraded in intracellular organellae (i. e. receptor mediated degradation). The lysosomes are the main sites of receptor-mediated insulin degradation because chloroquine, an inhibitor of lysosomal proteolysis, inhibits insulin degradation and stimulates both an accumulation of intracellular insulin and insulin binding in several target cells (Marshall and Olefsky, 1979 , Kobayashi et al., 1980 , Plas and Desbuquois, 1982 . On the other hand, insulin molecules are also degraded by other mechanism such as the non-receptor mediated pathway in several tissue (Carpentier et al., 1979) .
The established cultures of human lymphocytes, specially the IM-9 line, have been widely used as a model system in the investigation of the insulin receptor, and it has been reported that IM-9 lymphocytes lost the receptor-mediated insulin degradation (Baldwin et al., 1980 , Misbin et al., 1980 , Sonne and Gliemann, 1980 , Saviolakis et al., 1981 , and Iwamoto et al., 1981 .
Human cultured lymphocytes (RPMI-1788 line) were introduced by Huang and Moore (1969) and these cells were shown to have insulin specific receptors on the plasma membranes (Kobayashi and Meek, 1977) .
We investigated insulin degradation of RPMI-1788 lymphocytes and studied the influence of chloroquine and bacitracin on insulin binding and degradation to test whether the loss of the receptor-mediated insulin degradation in IM-9 lymphocytes is the generalized mechanism of insulin degradation in human cultured lymphocytes. 
Results
Electron microscopy of these lymphocytes These lymphocytes possessed a small but significant number of lysosomes compared to other cells, and showed a large nucleus/ cytoplasma ratio which displayed lymphoblastoid properties. However, these lymphocytes have other intracellular organellae (i.e. Golgi complex, ribosomes, and mitochondria) like other cells (Fig. 1) . Column chromatography of insulin degradation We determined the nature of the [125I]-radioactive materials in the buffer and on the cells by Sephadex G-50 fine column chromatography.
After 60 min, 23.2 % of the radioactivity from the incubation buffer containing cells represented intact insulin as measured by the receptor-rebinding method (Table 1) . These degraded products were characterized by gel filtration. As shown in Fig. 4 A, The cell-associated radioactive materials also showed three peaks, but the major radioactive material was intact insulin (72. 
Discussion
We have characterized insulin degradation in human cultured lymphocytes (RPMI 1788 line) and found that the insulin was degraded mainly in the medium outside of the cells.
Recently Yokono et al. (1982) reported that human cultured lymphocytes, IM-9 cells, had insulin degrading enzyme on the plasma membrane and that this enzyme was shed into the media. In RPMI-1788 lymphocytes, insulin degrading enzyme may be leaked from the cell and degrade insulin molecules outside of the cell.
Chloroquine, a lysosomotropic agent, increases cell-associated insulin, and decreases receptor-mediated insulin degradation in adipocytes Olefsky, 1979, Kobayashi et al. 1980 ) and hepatocytes (Plas and Desbuquois, 1982) . It has been hypothesized that the increase in insulin binding in the presence of chloroquine is due to the decrease in insulin degradation by the inhibition of lysosomal function (Marshall and Olefsky, 1979 , Kobayashi et al., 1980 , and Plas and Desbuquois, 1982 . However, it was demonstrated that IM-9 lymphocytes lost receptor-mediated insulin degrading activity and that chloroquine did not decrease the insulin degradation (Baldwin et al. , 1980 , Misbin et al. , 1980 , Sonne and Gliemann, 1980 , Saviolakis et al., 1981 , and Iwamoto, et al., 1981 . Baldwin speculated that the IM-9 cell lost a mechanism that couples the binding of insulin to the receptor to a subsequent degrading step.
In RPMI-1788 lymphocytes, chloroquine did not decrease the insulin degradation. We found that these cells may lose the receptor-mediated insulin degradation as shown in IM-9 cells. Although these lymphocytes have a small but significant number of lysosomes, the lysosomes may not play an important role in the insulin degradation. These lymphocytes may lost the coupling mechanism between receptor binding and a subsequent degrading step.
Furthermore, Baldwin et al. (1980) reported that chloroquine did not increase insulin binding in IM-9 cell. In contrast, Iwamoto et al. (1981) reported that chloroquine increased insulin binding by increasing the receptor' s affinity for IM-9 cells. Regarding this discrepancy, Iwamoto et al. (1981) speculated that in the experiment of Baldwin et al., a high concentration of cells (more than 3 x 107 cells/ml) or prolonged incubation time of the experiment blunted the effect of chloroquine on insulin binding. We also found that chloroquine did not increase insulin binding in RPMI-1788 cells in the experimental condition at a low concentration of cells (1.0 x 106 cells/ ml) similar to Iwamoto et al. (1981) . Thus, RPMI-1788 cells lost receptor-mediated degradation as shown in IM-9 cells, but chloroquine may not affect insulin binding in RPMI-1788 cells in contrast to that in IM-9 cells.
Leupeptin and antipain, inhibitors of the lysosomal enzyme cathepsin B (Savion et al., 1980) 
